A Three-Part Phase 1b Bioavailability and Pharmacokinetics Study of Two Formulations of FDL169 in Healthy Subjects and Subjects With Cystic Fibrosis

Trial Profile

A Three-Part Phase 1b Bioavailability and Pharmacokinetics Study of Two Formulations of FDL169 in Healthy Subjects and Subjects With Cystic Fibrosis

Completed
Phase of Trial: Phase I/II

Latest Information Update: 31 Oct 2016

At a glance

  • Drugs FDL 169 (Primary) ; FDL 169
  • Indications Cystic fibrosis
  • Focus Pharmacokinetics
  • Sponsors Flatley Discovery Lab
  • Most Recent Events

    • 21 Oct 2016 Status changed from recruiting to completed.
    • 08 Aug 2016 Planned End Date changed from 1 Jul 2016 to 1 Sep 2016.
    • 08 Aug 2016 Planned primary completion date changed from 1 Jul 2016 to 1 Sep 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top